Levetiracetam for Canine Idiopathic Epilepsy: Comparative Outcomes, Serum Monitoring, and Intranasal Emergency Use

Bottom line

• Levetiracetam is a second-generation antiseizure medication used in dogs as both add-on and monotherapy; it acts at the synaptic vesicle protein 2A (SV2A) and is valued for a wide safety margin and minimal hepatic metabolism.
• In a 100-dog comparative study, caregiver-assessed outcomes with levetiracetam, zonisamide, or phenobarbital monotherapy were broadly similar, with most owners reporting a favorable result and a significant improvement in quality-of-life scores during treatment.
• Phenobarbital co-administration measurably lowers serum levetiracetam concentrations, so dogs on combined therapy frequently need higher levetiracetam exposure to reach concentrations considered effective in people.
• A single intranasal dose reached the lower end of the human reference concentration rapidly in healthy dogs, supporting interest in intranasal levetiracetam as an option for emergency seizure management when intravenous access is unavailable.
• No validated canine therapeutic range has been established; dosing is extrapolated from human targets and individualized clinically. Confirm all dosing against a current formulary.

Drug facts

• Class: Second-generation antiseizure medication (racetam; SV2A ligand)
• Mechanism: Binds synaptic vesicle protein 2A (SV2A), modulating synaptic neurotransmitter release (label-supported mechanism)
• Route/interval: Oral and parenteral formulations exist, including immediate- and extended-release oral products; intranasal use is investigational. Defer interval and dose to a current formulary.
• Indication: Off-label in dogs for idiopathic epilepsy, as add-on therapy and monotherapy; not FDA-approved for veterinary use
• Approval: Human drug (levetiracetam, originally Keppra); no veterinary FDA approval
• Label contraindications: Per human label, known hypersensitivity; use cautiously with significant renal impairment (renally cleared)
• Label common AEs: Sedation and transient behavioral or gastrointestinal effects are the most commonly reported in dogs; serious adverse effects are uncommon

A specific patient on levetiracetam?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=levetiracetam-canine-epilepsy

What the evidence shows

Comparative effectiveness against zonisamide and phenobarbital

The most direct comparison of levetiracetam against the two other commonly used canine antiseizure drugs comes from a retrospective study with a caregiver questionnaire. Gristina and colleagues (2023) evaluated 100 dogs with idiopathic epilepsy treated with levetiracetam (n = 34), zonisamide (n = 31), or phenobarbital (n = 35) as monotherapy, drawing on medical-record review and owner survey responses (Gristina 2023, https://avmajournals.avma.org/view/journals/javma/261/7/javma.22.10.0469.xml).

Across all three drugs, owners reported a significant improvement in mean quality-of-life score during monotherapy (7.7; SD 2.14) compared with before treatment (6.25; SD 2.63; P < .0001), with no difference identified between the three monotherapy groups. The pattern of adverse effects did differ by drug: reported adverse effects were significantly more common in the phenobarbital group (77%, 27 of 35) and least common in the zonisamide group (39%, 12 of 31; P = .0066). Treatment-failure rates were 51% for phenobarbital, 35% for levetiracetam, and 45% for zonisamide, with failure most often attributed to inadequate seizure control; no significant difference was identified between groups in the rate of or time to failure.

The authors concluded that most caregivers reported a favorable outcome with any of the three monotherapies, that phenobarbital carried the highest reported burden of adverse effects without a corresponding difference in quality of life, and that prospective controlled studies are still needed to compare efficacy and safety directly. This is the central caveat for interpreting levetiracetam monotherapy: the supporting human-extrapolated and observational evidence is encouraging but not yet confirmed by controlled veterinary trials.

Serum concentrations, the phenobarbital interaction, and the absence of a canine therapeutic range

A practical obstacle to levetiracetam dosing in dogs is that the factors governing its serum concentrations — and any target range — are poorly defined. Saint-Maxent and colleagues (2024) examined 69 client-owned dogs with epilepsy treated with levetiracetam alone or in combination, using 127 trough serum levetiracetam measurements (Saint-Maxent 2024, https://europepmc.org/articles/PMC11256123).

Two findings are clinically important. First, the oral dose was the strongest determinant of serum concentration, and that relationship was stronger under monotherapy. Second, phenobarbital significantly decreased serum levetiracetam concentration in a dose-dependent manner — a recognized enzyme-induction interaction. As a result, dogs receiving both drugs generally require substantially higher levetiracetam exposure to reach the serum concentrations regarded as therapeutic in people. Critically, the investigators could not identify a discrete therapeutic range from their data.

The clinical translation is that levetiracetam monitoring in dogs cannot lean on a validated canine reference interval the way phenobarbital or bromide monitoring can. Where monitoring is used, trough sampling and attention to concurrent phenobarbital are the levers that matter most; the numeric dose itself should be set from a current formulary and individualized, not from any figure reproduced here.

Intranasal levetiracetam for emergency seizure management

Cluster seizures and status epilepticus demand rapid drug delivery, and intravenous access is not always available. Intranasal benzodiazepines are established for early seizure cessation, but longer-acting agents had not been characterized by this route in dogs until recently. Wagner and colleagues (2026) described the single-dose pharmacokinetics of a compounded intranasal levetiracetam product in nine healthy dogs in a randomized crossover design against an intravenous dose (Wagner 2026, https://europepmc.org/articles/PMC12968516).

The intranasal route achieved minimum target concentrations (defined in the study as the lower reference of 5 micrograms/mL) rapidly — within roughly the first half-hour on average — and maintained them for several hours, with a bioavailability of about 70%. The authors noted, however, that a single intranasal dose did not reach the high end of the reference interval in any dog, concluding that intranasal levetiracetam may be a viable alternative for emergent seizure management when intravenous access is unavailable, but that multiple doses may be required to achieve seizure cessation in some patients. This positions intranasal levetiracetam as a promising bridging option pending larger and clinical-outcome studies, rather than an established protocol.

How this fits clinical practice

Levetiracetam occupies a useful niche in canine epilepsy: a favorable safety profile, minimal hepatic involvement, and comparative outcomes that — on current observational evidence — are broadly similar to zonisamide and phenobarbital, with fewer reported adverse effects than phenobarbital. Its main practical limitations are the lack of a validated canine therapeutic range and the well-documented phenobarbital interaction that lowers its serum concentrations. Decisions about whether to use it as monotherapy or add-on, how to dose it, and how to adjust when combined with phenobarbital should follow current formulary guidance, therapeutic drug monitoring where appropriate, and individual clinical judgment. The intranasal data are an encouraging early signal for emergency use but are not yet a substitute for established benzodiazepine-based seizure-emergency protocols. None of the dose or concentration figures discussed here should be used as a prescribing instruction.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=levetiracetam-canine-epilepsy

References

1. Gristina BR, Waldron RJ, Nettifee JA, Munana KR. 2023. Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. J Am Vet Med Assoc 261(7):1020-1027. https://avmajournals.avma.org/view/journals/javma/261/7/javma.22.10.0469.xml
2. Saint-Maxent M, Juette T, Parent J, Castel A, Parmentier T. 2024. Factors influencing serum concentrations of levetiracetam in dogs with epilepsy. J Vet Intern Med 38(4):2249-2256. https://europepmc.org/articles/PMC11256123
3. Wagner JL, Foss KD, Reinhart JM, Forsythe LE. 2026. Single-Dose Pharmacokinetics of Intranasal Levetiracetam in Healthy Dogs. J Vet Pharmacol Ther 49(2):110-119. https://europepmc.org/articles/PMC12968516

Changelog

• 2026-06-19: First published.

Related reads

• Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring
• Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval and Clinical Evidence